Key result
Long-term administration of tolvaptan significantly improved cardiac-related death-free or heart failure-related hospitalization-free survival compared to conventional diuretics in patients with heart failure and chronic kidney disease.
Why the study?
Does long-term tolvaptan improve cardiac-related death-free or HF-related hospitalization-free survival in patients with heart failure and chronic kidney disease?
Cohort (n=102)
No
Does long-term tolvaptan improve cardiac-related death-free or HF-related hospitalization-free survival in patients with heart failure and chronic kidney disease?
Long-term administration of tolvaptan in patients with heart failure and chronic kidney disease is well-tolerated and associated with improved cardiac-related death-free or HF-related hospitalization-free survival compared to conventional diuretics.
May support tolvaptan in HF-CKD; hypothesis-generating and leaves open need for RCTs.
No takes yet. Share an insight, caveat, or question.
Uemura et al. (2017) conducted a cohort in Heart failure and chronic kidney disease (n=102). Tolvaptan vs. High-dose loop diuretics (≥60 mg) alone was evaluated on Cardiac-related death-free or HF-related hospitalization-free survival. Long-term administration of tolvaptan significantly improved cardiac-related death-free or heart failure-related hospitalization-free survival compared to conventional diuretics in patients with heart failure and chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: